Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes
| Autor: | Ron H.N. van Schaik, Jaap Verweij, Trinet Rietveld, Wilfried J. Graveland, Lena E. Friberg, William D. Figg, Erin R. Lepper, Floris A. de Jong, Peter de Bruijn, Ron H.J. Mathijssen, Alex Sparreboom |
|---|---|
| Přispěvatelé: | Medical Oncology, Clinical Chemistry, Internal Medicine, Erasmus MC other |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Cancer Research CYP3A Midazolam Biology Pharmacology Irinotecan Drug Administration Schedule Gene Expression Regulation Enzymologic Cytochrome P-450 Enzyme System SDG 3 - Good Health and Well-being Pharmacokinetics Predictive Value of Tests Cytochrome P-450 CYP3A Confidence Intervals medicine Humans Carbon Radioisotopes Prospective Studies Enzyme Inhibitors Glucuronosyltransferase Chromatography High Pressure Liquid Aged CYP3A4 Area under the curve Middle Aged Antineoplastic Agents Phytogenic Erythromycin breath test Erythromycin Gene Expression Regulation Neoplastic Phenotype Breath Tests Oncology Area Under Curve Camptothecin Female medicine.drug |
| Zdroj: | Journal of the National Cancer Institute, 96(21), 1585-1592. Oxford University Press |
| ISSN: | 1460-2105 0027-8874 |
| DOI: | 10.1093/jnci/djh298 |
| Popis: | textabstractBACKGROUND: Irinotecan is a topoisomerase I inhibitor that has been approved for use as a first- and second-line treatment for colorectal cancer. The response to irinotecan is variable, possibly because of interindividual variation in the expression of the enzymes that metabolize irinotecan, including cytochrome P450 3A4 (CYP3A4) and uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). We prospectively explored the relationships between CYP3A phenotype, as assessed by erythromycin metabolism and midazolam clearance, and the metabolism of irinotecan and its active metabolite SN-38. METHODS: Of the 30 white cancer patients, 27 received at least two treatments with irinotecan administered as one 90-minute infusion (dose, 600 mg) with 3 weeks between treatments, and three received only one treatment. Before the first and second treatments, patients underwent an erythromycin breath test and a midazolam clearance test as phenotyping probes for CYP3A4. Erythromycin metabolism was assessed as the area under the curve for the flux of radioactivity in exhaled CO2 within 40 minutes after administration of [N-methyl-14C]erythromycin. Midazolam and irinotecan were measured by high-performance liquid chromatography. Genomic DNA was isolated from blood and screened for genetic variants in CYP3A4 and UGT1A1. All statistical tests were two-sided. RESULTS: CYP3A4 activity varied sevenfold (range = 0.223%-1.53% of dose) among patients, whereas midazolam clearance varied fourfold (range = 262-1012 mL/min), although intraindividual variation was small. Erythromycin metabolism was not statistically significantly associated with irinotecan clearance (P = .090), whereas midazolam clearance was highly correlated with irinotecan clearance (r = .745, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|